DGAP-News

CORRECTION: CVR Medical Granted IRB Approval by Thomas Jefferson University

DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous CORRECTION: CVR Medical Granted IRB Approval by Thomas Jefferson University 18.01.2017 / 09:01 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - January 18, 2017) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') issues correction on the following statement regarding the conduction of clinical trials, previously posted on January 12, 2017:

CVR Medical Corp. is pleased to announce that its 'Carotid Stenotic Scan
(CSS)' device has received IRB approval for clinical trials, to be
conducted through the Jefferson Clinical Research Institute at Thomas
Jefferson University under the supervision of Dr. David J. Whellan.

CVR Chief Operations Officer Tony Robinson states, 'With this approval, we
look forward to moving into the next phase of our device's, and our
company's development. To be able to do so with Dr. Whellan at Thomas
Jefferson is something CVR is very proud of.'

For additional information on the organization, leadership, and current
news please visit the newly launched company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture
with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in
the medical industry focused on the commercialization of a proprietary
subsonic, infrasonic, and low frequency sound wave analysis technology and
has patents to a diagnostic device designed to detect and measure carotid
arterial stenosis. CVR Medical is managed by a proven technical team. CVR
Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:

(signed) 'Peter Bakema'

CEO, President & Director

For further information contact:

Brisco Capital Partners Corp.

Scott Koyich, President

Telephone: [phone]

This press release contains forward-looking information that involves